| 1.1 Primary: BPD symptom severity (continuous) |
23 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.1.1 End of treatment |
22 |
1244 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.52 [‐0.70, ‐0.33] |
| 1.1.2 0‐6 months follow‐up |
2 |
41 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.59 [‐1.23, 0.05] |
| 1.1.3 6‐12 months follow‐up |
2 |
157 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.04 [‐0.36, 0.27] |
| 1.1.4 12 months and over follow‐up |
2 |
97 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.94 [‐2.58, 0.70] |
| 1.2 Primary: BPD symptom severity (dichotomous), at above 12 months follow‐up |
1 |
|
Risk Ratio (IV, Fixed, 95% CI) |
Subtotals only |
| 1.3 Primary: self‐harm (continuous) |
13 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.3.1 End of treatment |
13 |
616 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.32 [‐0.49, ‐0.14] |
| 1.3.2 0‐6 months follow‐up |
1 |
28 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.52 [‐1.28, 0.23] |
| 1.3.3 6‐12 months follow‐up |
3 |
174 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.18 [‐0.48, 0.12] |
| 1.4 Primary: self‐harm (dichotomous) |
6 |
|
Risk Ratio (IV, Random, 95% CI) |
Subtotals only |
| 1.4.1 End of treatment |
6 |
513 |
Risk Ratio (IV, Random, 95% CI) |
0.85 [0.63, 1.14] |
| 1.4.2 0‐6 months follow‐up |
1 |
41 |
Risk Ratio (IV, Random, 95% CI) |
0.14 [0.04, 0.56] |
| 1.4.3 6‐12 months follow‐up |
1 |
41 |
Risk Ratio (IV, Random, 95% CI) |
0.27 [0.10, 0.68] |
| 1.4.4 12 months and over follow‐up |
1 |
41 |
Risk Ratio (IV, Random, 95% CI) |
0.33 [0.15, 0.76] |
| 1.5 Primary: suicide‐related outcomes (continuous) |
13 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.5.1 End of treatment |
13 |
666 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.34 [‐0.57, ‐0.11] |
| 1.5.2 0‐6 months follow‐up |
2 |
36 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.43 [‐1.10, 0.23] |
| 1.5.3 6‐12 months follow‐up |
2 |
109 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.42 [‐0.80, ‐0.04] |
| 1.5.4 Above 12 months follow‐up |
1 |
76 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.31 [‐0.77, 0.14] |
| 1.6 Primary: suicide‐related outcomes (dichotomous) |
5 |
|
Risk Ratio (IV, Random, 95% CI) |
Subtotals only |
| 1.6.1 End of treatment |
5 |
396 |
Risk Ratio (IV, Random, 95% CI) |
0.27 [0.11, 0.67] |
| 1.6.2 0‐6 months follow‐up |
1 |
41 |
Risk Ratio (IV, Random, 95% CI) |
0.25 [0.06, 1.05] |
| 1.6.3 Above 12 months follow‐up |
1 |
41 |
Risk Ratio (IV, Random, 95% CI) |
0.29 [0.11, 0.74] |
| 1.7 Primary: psychosocial functioning (continuous) |
23 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.7.1 End of treatment |
22 |
1314 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.45 [‐0.68, ‐0.22] |
| 1.7.2 0‐6 months follow‐up |
1 |
9 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.23 [‐2.74, 0.29] |
| 1.7.3 6‐12 months follow‐up |
3 |
247 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.09 [‐0.40, 0.23] |
| 1.7.4 Above 12 months follow‐up |
6 |
499 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.27 [‐0.60, 0.05] |
| 1.8 Secondary: anger (continuous) |
8 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.8.1 End of treatment |
8 |
323 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.38 [‐0.64, ‐0.12] |
| 1.8.2 0‐6 months follow‐up |
1 |
8 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.20 [‐2.82, 0.41] |
| 1.8.3 6‐12 months follow‐up |
2 |
111 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.12 [‐0.50, 0.25] |
| 1.8.4 Above 12 months follow‐up |
1 |
80 |
Std. Mean Difference (IV, Random, 95% CI) |
0.02 [‐0.42, 0.46] |
| 1.9 Secondary: affective instability (continuous) |
12 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.9.1 End of treatment |
12 |
620 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.68 [‐0.98, ‐0.39] |
| 1.9.2 6‐12 months follow‐up |
1 |
33 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.52 [‐1.21, 0.18] |
| 1.10 Secondary: chronic feelings of emptiness (continuous) |
4 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.10.1 End of treatment |
4 |
187 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.39 [‐0.69, ‐0.10] |
| 1.10.2 6‐12 months follow‐up |
1 |
33 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.58 [‐1.28, 0.11] |
| 1.11 Secondary: impulsivity (continuous) |
10 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.11.1 End of treatment |
10 |
491 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.54 [‐0.84, ‐0.25] |
| 1.11.2 6‐12 months follow‐up |
2 |
77 |
Std. Mean Difference (IV, Random, 95% CI) |
0.32 [‐0.13, 0.77] |
| 1.12 Secondary: impulsivity (dichotomous), at end of treatment |
1 |
|
Risk Ratio (IV, Fixed, 95% CI) |
Subtotals only |
| 1.13 Secondary: interpersonal problems (continuous) |
18 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.13.1 End of treatment |
18 |
1159 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.42 [‐0.68, ‐0.16] |
| 1.13.2 0‐6 months follow‐up |
1 |
53 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.41 [‐1.01, 0.20] |
| 1.13.3 6‐12 months follow‐up |
2 |
132 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.17 [‐0.65, 0.32] |
| 1.13.4 Above 12 months follow‐up |
3 |
172 |
Std. Mean Difference (IV, Random, 95% CI) |
0.00 [‐0.54, 0.54] |
| 1.14 Secondary: abandonment (continuous) |
2 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.14.1 End of treatment |
2 |
84 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.22 [‐0.66, 0.21] |
| 1.14.2 6‐12 months follow‐up |
1 |
33 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.39 [‐1.08, 0.30] |
| 1.15 Secondary: identity disturbance (continuous) |
4 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.15.1 End of treatment |
4 |
250 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.37 [‐0.84, 0.10] |
| 1.15.2 6‐12 months follow‐up |
1 |
33 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.09 [‐1.83, ‐0.35] |
| 1.16 Secondary: dissociation and psychotic‐like symptoms (continuous) |
6 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.16.1 End of treatment |
6 |
244 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.47 [‐0.85, ‐0.10] |
| 1.16.2 0‐6 months follow‐up |
2 |
35 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.97 [‐1.69, ‐0.26] |
| 1.16.3 6‐12 months follow‐up |
1 |
33 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.59 [‐1.29, 0.11] |
| 1.16.4 12 months and over follow‐up |
1 |
24 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.01 [‐0.81, 0.79] |
| 1.17 Secondary: depression (continuous) |
22 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.17.1 End of treatment |
22 |
1568 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.39 [‐0.61, ‐0.17] |
| 1.17.2 0‐6 months follow‐up |
4 |
125 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.80 [‐1.26, ‐0.34] |
| 1.17.3 6‐12 months follow‐up |
3 |
260 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.40 [‐0.95, 0.16] |
| 1.17.4 12 months and over follow‐up |
5 |
311 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.40 [‐0.74, ‐0.06] |
| 1.18 Secondary: depression (dichotomous), at end of treatment |
1 |
|
Risk Ratio (IV, Fixed, 95% CI) |
Subtotals only |
| 1.19 Secondary: attrition (dichotomous) |
33 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 1.19.1 End of treatment |
32 |
2225 |
Risk Ratio (M‐H, Random, 95% CI) |
1.00 [0.83, 1.20] |
| 1.19.2 0‐6 months follow‐up |
1 |
60 |
Risk Ratio (M‐H, Random, 95% CI) |
0.58 [0.34, 1.00] |
| 1.20 Secondary: non‐serious adverse effects (dichotomous), at end of treatment |
2 |
381 |
Risk Ratio (M‐H, Random, 95% CI) |
0.92 [0.45, 1.88] |
| 1.21 Secondary: serious adverse effects (dichotomous), at end of treatment |
4 |
571 |
Risk Ratio (IV, Fixed, 95% CI) |
0.86 [0.14, 5.09] |
